Hence, down-regulation of NKG2A on NK cells increases antitumor activity against HLA-E expressing resistant tumor cells [32] and blocking NKG2A in combination with the PD-1/PD-L1 pathway improves tumor control [33]. The gene discussed is CD274; the disease is neoplasm.